Thread by @StephenVLiu

#DCLUNG19 Daunting task of all non-EGFR/ALK drivers in #NSCLC handled easily by @alexdrilon - in #ROS1, note that not all ALK inhibitors are ROS1 inhibitors. Variation in CNS activity. Many active drugs to consider. #LCSM #LCAM

#DCLUNG19 Highly active, CNS penetrant and well tolerated TKIs for #RET and #NTRK fusion positive cancers, outlined by expert @alexdrilon

#DCLUNG19 Dabrafenib and trametinib active in #BRAF but be sure it’s V600E! Three drugs with breakthrough designation for #METex14. HER2 is a target but not copy number for #NSCLC, its mutations (usually ex20). #LCSM #LCAM

#DCLUNG19 Novel #KRAS inhibitors are mutant selective and engage the inactive conformation and lock it in that state. Tremendous early activity with 7 drugs in development/trials. #LCDM #LCAM

#DCLUNG19 More targets on the way - including #NRG1, with @alexdrilon noting early responses and referencing work by @SushmaJonna #LCSM #LCAM #OncoAlert